BioRegenx, Inc. (BRGX)

BioRegenx Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	1.85	2.34	3.41	0.04	3.99
Revenue Growth (YoY)	-20.75%	-31.40%	7991.78%	-98.94%	-48.79%
Cost of Revenue	0.35	0.68	1.1	0.05	1.43
Gross Profit	1.5	1.66	2.31	-0.01	2.56
Selling, General & Admin	2.02	6.03	5.72	0.06	5.81
Amortization of Goodwill & Intangibles	-	2.18	-	0.01	-
Operating Expenses	2.02	8.21	5.72	0.07	5.81
Operating Income	-0.52	-6.55	-3.41	-0.08	-3.25
Interest Expense	-0.3	-0.29	-0.19	-	-0.45
Interest & Investment Income	-	-	-	-	0.03
EBT Excluding Unusual Items	-0.82	-6.84	-3.6	-0.08	-3.67
Merger & Restructuring Charges	-	-	-	-	-0.01
Gain (Loss) on Sale of Investments	-	-	-	-	0
Asset Writedown	-0.73	-16.21	-	-	-1.11
Other Unusual Items	-	-	-	-	0.07
Pretax Income	-1.54	-23.05	-3.6	-0.08	-4.72
Net Income	-1.54	-23.05	-3.6	-0.08	-4.72
Net Income to Common	-1.54	-23.05	-3.6	-0.08	-4.72
Shares Outstanding (Basic)	960	912	640	270	35
Shares Outstanding (Diluted)	960	912	640	270	35
Shares Change (YoY)	5.19%	42.61%	137.18%	664.87%	1.01%
EPS (Basic)	-0.00	-0.03	-0.01	-0.00	-0.13
EPS (Diluted)	-0.00	-0.03	-0.01	-0.00	-0.13
Free Cash Flow	0.03	-0.51	-1.52	-0.06	-3.96
Free Cash Flow Per Share	-	-0.00	-0.00	-	-0.11
Gross Margin	81.08%	70.87%	67.76%	-25.52%	64.13%
Operating Margin	-27.98%	-279.93%	-99.92%	-185.74%	-81.57%
Profit Margin	-83.23%	-985.17%	-105.53%	-185.74%	-118.37%
Free Cash Flow Margin	1.61%	-21.95%	-44.41%	-153.35%	-99.39%
EBITDA	-0.44	-4.33	-3.4	-0.07	-3.25
EBITDA Margin	-23.94%	-185.10%	-99.78%	-174.42%	-81.55%
D&A For EBITDA	0.08	2.22	0	0	0
EBIT	-0.52	-6.55	-3.41	-0.08	-3.25
EBIT Margin	-27.98%	-279.93%	-99.92%	-185.74%	-81.56%
Revenue as Reported	1.85	2.34	3.41	-	-
Advertising Expenses	0.08	0.07	-	0.01	-

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.